Table 1

Correlation between CDCA3 expression and clinical classification in OSCCs
Results of immunostaining
Clinical classification No. patients (%)
Total CDCA3 negative CDCA3 positive p value
Age at surgery (years)
<60 23 9 (39) 14 (61)
≧60, <70 22 11 (50) 11 (50) 0.852
≧70 50 22 (44) 28 (56)
Gender
Male 58 28 (48) 30 (52) 0.317
Female 37 14 (38) 23 (62)
T-primary tumor
T1 6 3 (50) 3 (50) 0.020*
T2 56 30 (54) 26 (46)
T3 15 5 (33) 10 (67)
T4 18 4 (22) 14 (78)
T1 + T2 62 33 (53) 29 (47) 0.015*
T3 + T4 33 9 (27) 24 (73)
N-regional lymph node
N (−) 56 25 (45) 31 (55) 0.919
N (+) 39 17 (44) 22 (56)
Stage
I 6 3 (50) 3 (50) 0.235
II 36 18 (50) 18 (50)
III 17 8 (47) 9 (53)
IV 36 13 (36) 23 (64)
Histopathologic type
Well 60 26 (43) 34 (57) 0.803
Moderately 31 14 (45) 17 (55)
Poorly 4 2 (50) 2 (50)
Tumor site
Gingiva 28 9 (32) 19 (68) 0.456
Tongue 51 25 (49) 26 (51)
Buccal mucosa 9 4 (44) 5 (56)
Oral floor 7 4 (57) 3 (43)

*p < 0.05.

Uchida et al.

Uchida et al. BMC Cancer 2012 12:321   doi:10.1186/1471-2407-12-321

Open Data